{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:30:52Z","timestamp":1786120252266,"version":"build-2736575974"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1097\/ftd.0b013e3182263ac4","type":"journal-article","created":{"date-parts":[[2011,10,4]],"date-time":"2011-10-04T13:49:03Z","timestamp":1317736143000},"page":"632-643","source":"Crossref","is-referenced-by-count":25,"title":["Use of Total and Unbound Imatinib and Metabolite LC-MS\/MS Assay to Understand Individual Responses in CML and GIST Patients"],"prefix":"10.1097","volume":"33","author":[{"given":"Frank","family":"Streit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz","family":"Binder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Hafke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Brandhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Braulke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Detlef","family":"Haase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Armbrust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliano","family":"Ramadori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Oellerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Walson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210129","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra020777","article-title":"Chronic myeloid leukemiaadvances in biology and new approaches to treatment.","volume":"349","author":"Goldman","year":"2003","journal-title":"N Engl J Med"},{"key":"R2-9-20210129","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/shem.2003.50034","article-title":"Molecular mechanisms of transformation by the BCR-ABL oncogene.","volume":"40","author":"Sattler","year":"2003","journal-title":"Semin Hematol"},{"key":"R3-9-20210129","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.","volume":"347","author":"Demetri","year":"2002","journal-title":"N Engl J Med"},{"key":"R4-9-20210129","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1182\/blood-2003-06-1824","article-title":"The FIP1L1-PDGFR fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.","volume":"103","author":"Gotlib","year":"2004","journal-title":"Blood"},{"key":"R5-9-20210129","doi-asserted-by":"crossref","first-page":"9359","DOI":"10.1200\/JCO.2005.03.2185","article-title":"Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.","volume":"23","author":"Reardon","year":"2005","journal-title":"J Clin Oncol"},{"key":"R6-9-20210129","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic phase chronic myeloid leukemia: a subanalysis of the IRIS study.","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"R7-9-20210129","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/leu.2009.88","article-title":"Pharmacokinetic\/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia.","volume":"23","author":"Cortes","year":"2009","journal-title":"Leukemia"},{"key":"R8-9-20210129","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia.","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"R9-9-20210129","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00228-009-0621-z","article-title":"Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders.","volume":"65","author":"Singh","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"R10-9-20210129","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2008.20.4818","article-title":"Imatinib plasma levels are correlated with clinical benefit in patients with unresectable\/metastatic gastrointestinal stromal tumors.","volume":"27","author":"Demetri","year":"2009","journal-title":"J Clin Oncol"},{"key":"R11-9-20210129","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2125.2006.02719.x","article-title":"Population pharmacokinetics of imatinib and role of alpha-1-acid glycoprotein.","volume":"62","author":"Widmer","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"R12-9-20210129","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.2007.13.3819","article-title":"Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.","volume":"26","author":"Gibbons","year":"2008","journal-title":"J Clin Oncol"},{"key":"R13-9-20210129","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2165\/00003088-200847080-00001","article-title":"Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology.","volume":"47","author":"Zandvliet","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"R14-9-20210129","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jchromb.2009.04.045","article-title":"Therapeutic drug monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.","volume":"877","author":"Haouala","year":"2009","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R15-9-20210129","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/j.jchromb.2009.04.028","article-title":"New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma.","volume":"877","author":"De Francia","year":"2009","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R16-9-20210129","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1586\/14737140.8.9.1387","article-title":"Abl tyrosine kinase inhibitors for overriding Bcr-Abl\/T315I: from the second to third generation.","volume":"8","author":"Tanaka","year":"2008","journal-title":"Expert Rev Anticancer Ther"},{"key":"R17-9-20210129","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1056\/NEJMe1004430","article-title":"Even better kinase inhibitors for chronic myeloid leukemia.","volume":"363","author":"Sawyers","year":"2010","journal-title":"N Engl J Med"},{"key":"R18-9-20210129","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1186\/1471-2407-10-438","article-title":"Imatinib induced severe skin reactions and neutropenia in a patient with gastrointestinal stromal tumor.","volume":"10","author":"Hwang","year":"2010","journal-title":"BMC Cancer"},{"key":"R19-9-20210129","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/annonc\/mdp143","article-title":"Chronic myelogenous leukemia: ESMO Clinical Recommendations for diagnosis, treatment and follow-up.","volume":"20S","author":"Baccarani","year":"2009","journal-title":"Ann Oncol"},{"key":"R20-9-20210129","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1592\/phco.24.16.1508.50958","article-title":"The influence of St. Johns wort on the pharmacokinetics and protein binding of imatinib mesylate.","volume":"24","author":"Smith","year":"2004","journal-title":"Pharmacotherapy"},{"key":"R21-9-20210129","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","article-title":"OCT-1 mediated influx is the cause of low in vitro sensitivity to imatinib.","volume":"108","author":"White","year":"2006","journal-title":"Blood"},{"key":"R22-9-20210129","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/sj.clpt.6100201","article-title":"Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype.","volume":"82","author":"Gurney","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"R23-9-20210129","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.leukres.2009.11.009","article-title":"Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography.","volume":"34","author":"Davies","year":"2010","journal-title":"Leuk Res"},{"key":"R24-9-20210129","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/sj.bjc.6604355","article-title":"Relationship of imatinib free plasma levels and target genotype with efficacy and tolerability.","volume":"98","author":"Widmer","year":"2008","journal-title":"Br J Cancer"},{"key":"R25-9-20210129","doi-asserted-by":"crossref","first-page":"G98","DOI":"10.1016\/j.leukres.2009.12.009","article-title":"Tyrosine kinase inhibitors concentration monitoring in chronic myeloid leukemia.","volume":"34","author":"Widmer","year":"2010","journal-title":"Leuk Res"},{"key":"R27-9-20210129","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1373\/clinchem.2003.024323","article-title":"Validation of a rapid and sensitive liquid chromatography-tandem mass spectrometry method for free and total mycophenolic acid.","volume":"50","author":"Streit","year":"2004","journal-title":"Clin Chem"},{"key":"R28-9-20210129","first-page":"955","article-title":"Rapid liquid chromatography-tandem mass spectrometry routine method for simultaneous determination of sirolimus, everolimus, tacrolimus and cyclosporine A in whole blood, Clin Chem.","volume":"48","author":"Streit","year":"2002","journal-title":""},{"key":"R29-9-20210129","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/FTD.0b013e3181817318","article-title":"Determination of unbound antiretroviral drug concentrations by a modified ultrafiltration method reveals high variability in the free fraction.","volume":"30","author":"Fayet","year":"2008","journal-title":"Ther Drug Monit"},{"key":"R30-9-20210129","doi-asserted-by":"crossref","first-page":"6073","DOI":"10.1158\/1078-0432.CCR-05-2596","article-title":"Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumours.","volume":"12","author":"Debaldo","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R31-9-20210129","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1365-2125.2004.02117.x","article-title":"In vitro blood distribution and plasma protein binding of the tyrosine kinase inhibitor imatinib and its active metabolite, CGP74588, in rat, dog, monkey, healthy humans and patients with acute myelogenous leukemia.","volume":"58","author":"Kretz","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"R33-9-20210129","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1182\/blood-2007-03-079871","article-title":"Therapeutic drug monitoring in CML patients on imatinib.","volume":"110","author":"Blasdel","year":"2007","journal-title":"Blood"},{"key":"R34-9-20210129","first-page":"7104","article-title":"Azard J, et al on behalf of the Innovative Therapies with Children with Cancer European consortium. Population pharmacokinetics of imatinib in children and adults.","volume":"14","author":"Petain","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R35-9-20210129","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00228-009-0779-4","article-title":"Integrating pharmacogenetics and therapeutic drug monitoring: optimal dosing of imatinib as a case-example.","volume":"66","author":"Li-Wang-Po","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"R36-9-20210129","first-page":"625","article-title":"-1 Acid glycoprotein binds to imatinib (ST1571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients.","volume":"9","author":"Gambacorti-Passerini","year":"2003","journal-title":"Clin Cancer Res"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0b013e3182263ac4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:22:18Z","timestamp":1786047738000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007691-201110000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e3182263ac4","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}